Stockscreener 앱 받기
78.89
2.13%
-1.72
시간 외 거래:
78.89
전일 마감가:
$80.61
열려 있는:
$79.76
하루 거래량:
549.37K
Relative Volume:
0.88
시가총액:
$6.49B
수익:
$51.48M
순이익/손실:
$-315.00M
주가수익비율:
-22.09
EPS:
-3.5708
순현금흐름:
$-244.00M
1주 성능:
-4.04%
1개월 성능:
-11.13%
6개월 성능:
+19.46%
1년 성능:
+161.48%
1일 변동 폭
$78.32
$81.15
1주일 범위
$76.87
$83.41
52주 변동 폭
$28.06
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5314
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
78.89 | 6.63B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-06 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | 재개 | Guggenheim | Buy |
| 2025-10-24 | 재확인 | B. Riley Securities | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-20 | 재개 | Stifel | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Market Perform |
| 2024-12-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-26 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 개시 | Oppenheimer | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 개시 | Truist | Buy |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 개시 | Raymond James | Mkt Perform |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-08-03 | 개시 | Goldman | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | JP Morgan | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2021-09-30 | 개시 | B. Riley Securities | Neutral |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-09-15 | 개시 | BofA Securities | Neutral |
| 2020-09-15 | 개시 | Cowen | Outperform |
| 2020-09-15 | 개시 | Guggenheim | Buy |
| 2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera Therapeutics Inc. (KYMR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Eagle Health Investments LP Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
CCORF Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $106 - Moomoo
Kymera expects KT-579 phase I data in 2H 2026 while targeting KT-621 BROADEN2 enrollment completion by year-end - MSN
Which Is a Better Investment, Kymera Therapeutics, Inc. or Nurix Therapeutics, Inc. Stock? - AAII
Kymera presents KT-621 atopic dermatitis trial data at conferences - Investing.com UK
Kymera Therapeutics (KYMR) Valuation Check After New KT-621 And KT-579 Clinical And Preclinical Progress - Yahoo Finance
T. Rowe Price reports 5.46M-share stake in Kymera (KYMR) - Stock Titan
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses - Investing News Network
Kymera presents KT-621 atopic dermatitis trial data at conferences By Investing.com - Investing.com Nigeria
Wellington group holds 3.89M shares in Kymera (KYMR) — 4.76% stake - Stock Titan
Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral Stat6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses - marketscreener.com
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses - GlobeNewswire Inc.
Kymera Therapeutics stock (US50153V1061): Featured in psoriasis pipeline report - AD HOC NEWS
Why (KYMR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BTIG Maintains Kymera Therapeutics (KYMR) Buy Recommendation - MSN
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Kymera Therapeutics stock (US50153V1061): Director sells $261K in shares amid strong Q1 revenue - AD HOC NEWS
Law firm investigates Kymera Therapeutics for possible breach of fiduciary duties by directors - Pluang
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) - PR Newswire
Kymera Therapeutics director Elena Ridloff sells $261,000 in stock By Investing.com - Investing.com Australia
Kymera Therapeutics director Elena Ridloff sells $261,000 in stock - Investing.com
Kymera (KYMR) director Ridloff exercises options, sells 3,000 shares under 10b5-1 plan - Stock Titan
KYMR (KYMR) Form 144: 3,000-share sale; prior 10b5-1 sales disclosed - Stock Titan
Kymera Therapeutics stock (US50153V1061): Up after Q1 beat and new IBD data for KT-579 degrader cand - AD HOC NEWS
How The Kymera Therapeutics (KYMR) Story Is Shifting Around KT-621 And Degrader Potential - Yahoo Finance
State of New Jersey Common Pension Fund D Makes New $2.61 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
CCORF Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $106 - Moomoo
FMR LLC holds 14.3% of Kymera Therapeutics (NASDAQ: KYMR) in 13G/A - Stock Titan
Kymera Therapeutics to Participate in Upcoming May Investor Conferences - Investing News Network
Kymera’s IRF5 degrader shows potential in IBD treatment - BioWorld News
Canaccord Genuity Group Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
Vanguard Group Inc. Buys 845,922 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
UBS Group AG Buys 88,314 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Q2 EPS Estimate for Kymera Therapeutics Boosted by Analyst - MarketBeat
Kymera lines up two May investor webcasts from Las Vegas and New York - Stock Titan
Canaccord Genuity initiates coverage of Kymera Therapeutics (KYMR) with buy recommendation - MSN
Kymera presents preclinical data for IBD drug candidate KT-579 By Investing.com - Investing.com South Africa
Kymera presents preclinical data for IBD drug candidate KT-579 - Investing.com UK
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week - Investing News Network
Equities Analysts Issue Forecasts for KYMR Q2 Earnings - MarketBeat
Oral bowel disease drug matched approved therapies in preclinical tests - Stock Titan
Kymera Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:KYMR) 2026-05-04 - Seeking Alpha
Kymera Therapeutics Q1 2026 earnings preview - MSN
Kymera Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq
Kymera Therapeutics, Inc. Rings the Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq
H.C. Wainwright Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $134 - Moomoo
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Understanding Momentum Shifts in (KYMR) - Stock Traders Daily
Kymera Therapeutics Inc (KYMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):